Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Olaparib induces tumour response as single agent in BRCA-deficient breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.07.09
Views: 14783

Dr Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK

Andrew Tutt, MB, ChB, PhD, Kings College London, United Kingdom, speaking at ASCO 2009: PARP Inhibitor Olaparib Induces Tumor Response as Single Agent in BRCA-Deficient Breast Cancer: A small, Phase II international multi-center study reports that more than a third of women with BRCA1 or BRCA2 mutations and advanced breast cancer that persisted despite prior treatment experienced tumour shrinkage after receiving the investigational PARP inhibitor olaparib.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation